hotspot -WSS

hotspot

author：entertainment 2025-10-04 04:01:49 - browse：422

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Medicare drug price negotiation continues, as pharma counteroffers

WSS

First over

Longer MASH drug regimen improved liver, Akero study finds

State of the Union pitch: Bigger Medicare drug price negotiations

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

It's time to retire 'poor historian' from clinicians' vocabularies

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

hotspot

hotspot

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Glen Campbell's doctor discusses his public struggle with Alzheimer's

In Memoriam: Notable people who died in 2023

Readout Newsletter: BridgeBio, Akero, and human embryo models

In Memoriam: Notable people who died in 2023

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Hepatitis C has a cure — but many Americans still lack access to it

Criminal prosecution for violating HIPAA: an emerging threat

Drug repurposing or repositioning? The language matters

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

leisure time

Solving academic medical centers' existential crisis

Medicare drug price negotiation continues, as pharma counteroffers

When prostate cancer spreads, where it goes matters

Longer MASH drug regimen improved liver, Akero study finds

HIV vaccine remains elusive. Immunologists keep trying new ideas

Data integrity in scientific journals requires "effort" by publishers, institutions

explore

leisure time

focus

leisure time